Ahmaddy Freba, Wenter Vera, Ilhan Harun, Wacker Daniel, Unterrainer Marcus, Knösel Thomas, Bartenstein Peter, Spitzweg Christine, Lehner Sebastian, Todica Andrei
Department of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, Germany.
Institute of Pathology, Ludwig-Maximilians-University of Munich, 81377 Munich, Germany.
Cancers (Basel). 2020 Nov 13;12(11):3357. doi: 10.3390/cancers12113357.
Extrathyroidal extension of differentiated thyroid cancer is a poor outcome factor but seems to be less significant in minimal extrathyroidal extension (mETE). However, the impact of mETE on response rate after (adjuvant) initial radioactive iodine (RAI) therapy remains unclear. We therefore compared response rates of patients with classical and follicular variants of papillary thyroid cancer (PTC) according to the updated eighth tumor-node-metastasis (TNM) classification to a control group.
455 patients with T3 (primary tumor > 4 cm) PTC according to the seventh classification who underwent total thyroidectomy followed by RAI therapy were screened. Patients formerly classified as T3 PTC solely due to mETE were reclassified into patients with T1 (primary tumor ≤ 2 cm) or T2 (primary tumor > 2 cm but ≤ 4 cm) +mETE and compared to a control group of T1/T2 -mETE PTC patients.
138/455 patients were reclassified as T1/2 +mETE and compared to 317/455 T1/T2 -mETE control patients. At initial presentation, +mETE patients showed significantly higher rates of cervical lymph node metastases (-value 0.001). Response rates were comparable in both groups (-value n.s.). N1a/N1b-stage (Hazard ratio, HR 0.716; 95% CI 0.536-0.956, -value 0.024) was identified as an independent prognostic factor for lower response rates.
Response rates after RAI therapy were comparable in PTC patients irrespective of mETE but with higher rates of lymph node metastases.
分化型甲状腺癌的甲状腺外侵犯是一个预后不良因素,但在微小甲状腺外侵犯(mETE)中似乎不太显著。然而,mETE对(辅助)初始放射性碘(RAI)治疗后缓解率的影响仍不清楚。因此,我们根据更新的第八版肿瘤-淋巴结-转移(TNM)分类,将乳头状甲状腺癌(PTC)经典型和滤泡型患者的缓解率与对照组进行了比较。
筛选出455例根据第七版分类诊断为T3(原发肿瘤>4 cm)PTC且接受了甲状腺全切术及后续RAI治疗的患者。以前仅因mETE被分类为T3 PTC的患者被重新分类为T1(原发肿瘤≤2 cm)或T2(原发肿瘤>2 cm但≤4 cm)+mETE患者,并与T1/T2 -mETE PTC患者的对照组进行比较。
138/455例患者被重新分类为T1/2 +mETE,与317/455例T1/T2 -mETE对照患者进行比较。初次就诊时,+mETE患者的颈部淋巴结转移率显著更高(P值0.001)。两组的缓解率相当(P值无统计学意义)。N1a/N1b期(风险比,HR 0.716;95%可信区间0.536-0.956,P值0.024)被确定为缓解率较低的独立预后因素。
无论是否存在mETE,PTC患者RAI治疗后的缓解率相当,但淋巴结转移率更高。